IBDEI1CB ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,24013,0)
 ;;=098.0^^153^1528^1
 ;;^UTILITY(U,$J,358.3,24013,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24013,1,2,0)
 ;;=2^098.0
 ;;^UTILITY(U,$J,358.3,24013,1,5,0)
 ;;=5^Ac Gonococcal Infection
 ;;^UTILITY(U,$J,358.3,24013,2)
 ;;=^52567
 ;;^UTILITY(U,$J,358.3,24014,0)
 ;;=098.2^^153^1528^3
 ;;^UTILITY(U,$J,358.3,24014,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24014,1,2,0)
 ;;=2^098.2
 ;;^UTILITY(U,$J,358.3,24014,1,5,0)
 ;;=5^Chr Gonococcal Inf-Lower Urinary Tract
 ;;^UTILITY(U,$J,358.3,24014,2)
 ;;=^266794
 ;;^UTILITY(U,$J,358.3,24015,0)
 ;;=099.0^^153^1528^2
 ;;^UTILITY(U,$J,358.3,24015,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24015,1,2,0)
 ;;=2^099.0
 ;;^UTILITY(U,$J,358.3,24015,1,5,0)
 ;;=5^Chancroid
 ;;^UTILITY(U,$J,358.3,24015,2)
 ;;=^22199
 ;;^UTILITY(U,$J,358.3,24016,0)
 ;;=099.1^^153^1528^14
 ;;^UTILITY(U,$J,358.3,24016,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24016,1,2,0)
 ;;=2^099.1
 ;;^UTILITY(U,$J,358.3,24016,1,5,0)
 ;;=5^Lymphogranuloma Venereum
 ;;^UTILITY(U,$J,358.3,24016,2)
 ;;=^72538
 ;;^UTILITY(U,$J,358.3,24017,0)
 ;;=099.40^^153^1528^15
 ;;^UTILITY(U,$J,358.3,24017,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24017,1,2,0)
 ;;=2^099.40
 ;;^UTILITY(U,$J,358.3,24017,1,5,0)
 ;;=5^Non-Gonococcal Urethritis
 ;;^UTILITY(U,$J,358.3,24017,2)
 ;;=^293984
 ;;^UTILITY(U,$J,358.3,24018,0)
 ;;=099.2^^153^1528^7
 ;;^UTILITY(U,$J,358.3,24018,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24018,1,2,0)
 ;;=2^099.2
 ;;^UTILITY(U,$J,358.3,24018,1,5,0)
 ;;=5^Granuloma Inguinale
 ;;^UTILITY(U,$J,358.3,24018,2)
 ;;=^52876
 ;;^UTILITY(U,$J,358.3,24019,0)
 ;;=098.12^^153^1528^6
 ;;^UTILITY(U,$J,358.3,24019,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24019,1,2,0)
 ;;=2^098.12
 ;;^UTILITY(U,$J,358.3,24019,1,5,0)
 ;;=5^Gonococcal Prostatitis
 ;;^UTILITY(U,$J,358.3,24019,2)
 ;;=^266787
 ;;^UTILITY(U,$J,358.3,24020,0)
 ;;=996.64^^153^1528^10
 ;;^UTILITY(U,$J,358.3,24020,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24020,1,2,0)
 ;;=2^996.64
 ;;^UTILITY(U,$J,358.3,24020,1,5,0)
 ;;=5^Infected Catheter
 ;;^UTILITY(U,$J,358.3,24020,2)
 ;;=^276287
 ;;^UTILITY(U,$J,358.3,24021,0)
 ;;=996.65^^153^1528^11
 ;;^UTILITY(U,$J,358.3,24021,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24021,1,2,0)
 ;;=2^996.65
 ;;^UTILITY(U,$J,358.3,24021,1,5,0)
 ;;=5^Infected Device
 ;;^UTILITY(U,$J,358.3,24021,2)
 ;;=^276288
 ;;^UTILITY(U,$J,358.3,24022,0)
 ;;=596.81^^153^1528^12
 ;;^UTILITY(U,$J,358.3,24022,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24022,1,2,0)
 ;;=2^596.81
 ;;^UTILITY(U,$J,358.3,24022,1,5,0)
 ;;=5^Infection of Cystostomy
 ;;^UTILITY(U,$J,358.3,24022,2)
 ;;=^340556
 ;;^UTILITY(U,$J,358.3,24023,0)
 ;;=233.4^^153^1529^13
 ;;^UTILITY(U,$J,358.3,24023,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24023,1,2,0)
 ;;=2^233.4
 ;;^UTILITY(U,$J,358.3,24023,1,5,0)
 ;;=5^Prostate Carcinoma in Situ
 ;;^UTILITY(U,$J,358.3,24023,2)
 ;;=^267739
 ;;^UTILITY(U,$J,358.3,24024,0)
 ;;=185.^^153^1529^4
 ;;^UTILITY(U,$J,358.3,24024,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24024,1,2,0)
 ;;=2^185.
 ;;^UTILITY(U,$J,358.3,24024,1,5,0)
 ;;=5^Cancer, Prostate, Primary
 ;;^UTILITY(U,$J,358.3,24024,2)
 ;;=^99481
 ;;^UTILITY(U,$J,358.3,24025,0)
 ;;=198.82^^153^1529^5
 ;;^UTILITY(U,$J,358.3,24025,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24025,1,2,0)
 ;;=2^198.82
 ;;^UTILITY(U,$J,358.3,24025,1,5,0)
 ;;=5^Cancer, Prostate, Secondary
 ;;^UTILITY(U,$J,358.3,24025,2)
 ;;=^267339
 ;;^UTILITY(U,$J,358.3,24026,0)
 ;;=V10.46^^153^1529^7
 ;;^UTILITY(U,$J,358.3,24026,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,24026,1,2,0)
 ;;=2^V10.46
